Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has announced the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to its screening facilities in Hamburg, Germany.
Subscribe to our email newsletter
The Hamburg facility will be equipped with technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.
Agilent vice president biological systems division general manager Gustavo Salem said as the company plans to expand the platform into the European Contract Research market, considers Evotec as the ideal partner.
"Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard Mass Spectrometry platforms," Salem added.
RapidFire is an in-line solid phase extraction technology which allows ultrafast, direct analysis of native compounds for a range of biochemical assays such as routine ADME and lead discovery applications across a range of therapeutic areas.
Evotec chief operating officer Mario Polywka said, "The addition of Agilent’s RapidFire Mass Spectrometry analysis instrumentation and capabilities is a tremendous boost to Evotec’s best in class screening platform."